Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

In today’s episode, Jae Park, MD, discussed all things CAR T-cell therapy in acute lymphoblastic leukemia (ALL), touching on topics like where this treatment modality fits into the ALL paradigm, how it affects clinical practice, and how to go about selecting between the multiple FDA-approved options. Dr Park is the chief of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. 

In our exclusive interview, Dr Park began with a conversation about the November 2024 FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) and the October 2021 FDA approval of brexucabtagene autoleucel (brexu-cel; Tecartus) for patients with ALL. He explained how these CAR T-cell therapies fit into the ALL treatment paradigm for patients who have relapsed disease. After weighing how the safety and efficacy of each therapy stack up against others, Dr Park then discussed analyses that have come out after the obe-cel approval and their effect on obe-cel usage. Dr Park pointed out real-world studies presented at the 2025 ASH Annual Meeting, as well as analyses of the phase 1/2 FELIX trial (NCT04404660), which supported the approval of obe-cel. 

Finally, Dr Park looked ahead to the future of CAR T-cell therapies for ALL, noted in which settings he believes this class of agents will see the most use, and explained how to make treatment selections between therapies like brexu-cel and obe-cel.